Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024 Mar 11.
PMID: 38465573
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests. J Health Econ Outcomes Res. 2024; 11(1):32-43.
PMID: 38370007
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
PMID: 38324483
Macrophage RAGE activation is proinflammatory in NASH.
Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).
PMID: 38175729
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049.
PMID: 37845315
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
PMID: 37896803
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023 12; 79(6):1524-1541.
PMID: 37730124
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol. 2023 May 19; 23(1):160.
PMID: 37208593
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
PMID: 37162151
The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 Infection.
The Omicron Sub-Variant BA.4 Displays a Remarkable Lack of Clinical Signs in a Golden Syrian Hamster Model of SARS-CoV-2 Infection. Viruses. 2023 05 10; 15(5).
PMID: 37243219